IgE and IgG4 epitopes of the peanut allergens shift following oral immunotherapy

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Rambo, Ian M.
    • Other Affiliation: United States Department of Agriculture
  • Kronfel, Christina M.
    • Other Affiliation: United States Department of Agriculture
  • Rivers, Adam R.
    • Other Affiliation: United States Department of Agriculture
  • Swientoniewski, Lauren T.
    • Other Affiliation: United States Department of Agriculture
  • McBride, Jane K.
    • Other Affiliation: United States Department of Agriculture
  • Cheng, Hsiaopo
    • Other Affiliation: United States Department of Agriculture
  • Simon, Reyna J.
    • Other Affiliation: Aimmune Nestlé Health Science
  • Ryan, Robert
    • Other Affiliation: Aimmune Nestlé Health Science
  • Tilles, Stephen A.
    • Other Affiliation: Aimmune Nestlé Health Science
  • Nesbit, Jacqueline B.
    • Other Affiliation: Aimmune Nestlé Health Science
  • Kulis, Michael D.
    • Other Affiliation: Department of Pediatrics
  • Hurlburt, Barry K.
    • Other Affiliation: United States Department of Agriculture
  • Maleki, Soheila J.
    • Other Affiliation: United States Department of Agriculture
Abstract
  • Background Oral immunotherapy (OIT) with peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; Aimmune Therapeutics) is an FDA-approved treatment to desensitize peanut allergic participants. Objective Here we assessed shifts in IgE and IgG4 binding to peanut allergens and their epitopes recognized by United States (US) peanut allergic participants (n = 20) enrolled in phase 3 PTAH OIT clinical trials. Methods Pre- and post- trial participant sera were collected approximately 12 months apart and tested for IgE binding to intact peanut proteins via ImmunoCAP ISAC immunoassays. IgE and IgG4 linear epitopes were identified based on binding to synthetic overlapping 15-mer linear peptides of 10 peanut allergens (Ara h 1-11) synthesized on microarray slides. Results Statistically significant decreases in IgE binding were identified for intact Ara h 2, 3, and 6, and known and newly identified IgE epitopes were shown to exhibit shifts towards IgG4 binding post-OIT, with most linear peptides having increased IgG4 binding after treatment with PTAH. While PTAH does not seem to alter the actual peptide binding patterns significantly after one year of treatment, the IgE and IgG4 binding ratios and intensity are altered. Conclusion At a population level, the linear IgE and IgG4 epitopes of 10 peanut allergens overlap and that increase in IgG4 with OIT results in displacement of IgE binding to both conformational and linear epitopes. Furthermore, it appears as though the increase in IgG4 is more important to achieve desensitization at the 12-month timepoint than the decrease in IgE. This type of knowledge can be useful in the identification of IgE and IgG4-binding allergen and peptide biomarkers that may indicate desensitization or sustained unresponsiveness of allergic individuals to peanut.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Frontiers in Allergy
Journal volume
  • 4
Language
  • English
Version
  • Publisher
ISSN
  • 2673-6101
Publisher
  • Frontiers Media

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details falgy-04-1279290.pdf 2023-12-05 Public Download